FDA Approves Vyalev for Advanced Parkinson Disease
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for treatment of motor fluctuations
Demographics, Smell Test, and Cognitive Test Can Predict Cognitive Decline, Dementia
Combination provides cost-effective approach with accuracy comparable to positron emission tomography
Social Determinants of Health Linked to Receipt of Treatment for Stroke
Patients in highest quintile of Social Vulnerability Index less likely to receive thrombolysis, mechanical thrombectomy
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
Adding 75-mg vial size would achieve greatest reduction in waste, representing annual savings of $99 million
Retinal Neuroaxonal Loss Detectable With Epilepsy
People with a high number of antiseizure medications seem to be at risk for accelerated neuroaxonal loss
2013 to 2021 Saw Decline in Benzodiazepine Initiation Post-AIS
More than three-quarters of prescriptions were for a supply of more than seven days; 55 percent for 15 to 30 days
Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
TNK associated with higher likelihood of excellent functional outcome and reduced disability at three months
In Utero Exposure to COVID-19 Not Tied to Later Neurodevelopmental Issues
Findings seen for offspring evaluated through 24 months postpartum
Gut Flora Differs in Patients With Epilepsy and Cognitive Dysfunction
Collinsella, Oscillospirales, and Ruminococcaceae have a greater impact on epilepsy with cognitive dysfunction
Risk for Most Cardiovascular Events Reduced After COVID-19 Vaccination
Increased risk for myocarditis, pericarditis seen one to two weeks after COVID-19 mRNA vaccination
